oncology Archives | Be Korea-savvy

Home / Posts tagged oncology

TRIO Enrols First Patient in Global Phase 3 Giredestrant Early Breast Cancer Trial

EDMONTON, Alberta, Aug. 31 (Korea Bizwire) — Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment of first patient in the LidERA Breast Cancer (TRIO045) trial, a Phase 3 randomized, multi-center, open-label global clinical trial of adjuvant endocrine therapy, giredestrant (GDC-9545) sponsored by F. Hoffmann-LaRoche. Giredestrant is an oral selective [...]

TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule

EDMONTON, Alberta, July 6 (Korea Bizwire) — Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment completion in coopERA Breast Cancer (WO42133/TRIO038), a Phase 2 randomized, multi-center, open-label clinical trial of giredestrant (GDC-9545) sponsored by F. Hoffmann-La Roche. This comes shortly after completion of the planned study interim analysis provided [...]

George Clinical and Omico Align to Evolve Oncology Study Enrollment Through Genomic Profiling in Australia

SYDNEY, June 15 (Korea Bizwire) — George Clinical, a global scientifically-backed clinical research organization, and Omico, an Australian-based not-for-profit national precision oncology platform, have aligned to revolutionize oncology clinical trial access for patients and improve the efficiency of study enrollment. The two organizations began collaborating in late 2020 and announced the joint effort during the [...]

TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial

EDMONTON, Alberta, April 21 (Korea Bizwire) — Translational Research In Oncology (TRIO) today announced completion of enrollment for Novartis phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC). The trial, referred to as NATALEE (New Adjuvant TriAl with LEE), has enrolled 5101 patients globally. [...]

Philips Boosts Digital Pathology with Enhanced Informatics to Advance Precision Diagnosis in Oncology

Amsterdam, The Netherlands, Dec. 4 (Korea Bizwire) – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it will introduce its latest advancements in digital pathology at the European Congress of Pathology 2020 virtual event, Dec. 6-8. Building on its strong portfolio to support oncology clinical decision-making, Philips brings together the power [...]

Philips and MD Anderson Collaborate to Facilitate Personalized Oncology Treatments and Clinical Trial Matching Based on Genomic Markers

Amsterdam, the Netherlands, and Houston, US, June 16 (Korea Bizwire) – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and The University of Texas MD Anderson Cancer Center today announced a collaboration to provide oncologists with evidence-based therapy and clinical trial guidance through Philips’ oncology informatics solutions and MD Anderson’s Precision Oncology Decision Support (PODS) [...]

TRIO Enrolls First Patient Into PHASE III NATALEE Clinical Trial

EDMONTON, Alberta, Jan. 14 (Korea Bizwire) — Translational Research In Oncology (TRIO), in collaboration with Novartis and under the direction of Dennis Slamon, MD, PhD, TRIO Chairman/Executive Director and Director of Clinical Translational Research at the University of California, Los Angeles Jonsson Comprehensive Cancer Center, announces enrollment of the first patient into its newest clinical [...]

TRIO Awarded NATALEE Study, Largest Single Phase III Breast Cancer Clinical Trial in its History

EDMONTON, Alberta, Jul. 9 (Korea Bizwire) — Translational Research In Oncology (TRIO) today announced a collaboration with Novartis on its upcoming phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC). The trial will be called NATALEE (New Adjuvant TriAl with LEE). “Ribociclib in combination [...]